• 1
    Afdhal NH. Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology 2003; 37: 9724.
  • 2
    Gebo KA, Herlong HF, Torbenson MS, et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 2002; 36: S16172.
  • 3
    Poynard T, Ratziu V, Benhamou Y, Thabut D, Moussalli J. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?. Gastroenterology 2005; 128: 11468.
  • 4
    Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol. 2006; 12: 368294.
  • 5
    Bedossa P, Poynard T: an algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 28993.
  • 6
    Poynard T, Aubert A, Bedossa P, et al. A simple biological index for detection of alcoholic liver disease in drinkers.. Gastroenterology 1991; 100: 1397402.
  • 7
    Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C. virus METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 1997; 4: 199208.
  • 8
    Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV-Fibrosure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3: 8.
  • 9
    Poynard T, Imbert-Bismut F, Ratziu V, et al. Fibrotest even better than liver biopsy? Clin Chem 2003; Electronic letter Response: (21 March 2003)
  • 10
    Poynard T, Halfon P, Castera L, et al. La prevalence de chaque stade de variabilité est un facteur majeur de variabilité de l’estimation de la valeur diagnostique des marqueurs de fibrose par les courbes ROC. Gastroenterol Clin Biol 2006; 30: 1039.
  • 11
    Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003; 38: 48192.
  • 12
    Halfon P, Bourliere M, Deydier R, et al. Independent prospective multicenter validation of biochemical markers (Fibrotest-Actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C. Am J Gastro 2006; 101: 54755.
    Direct Link:
  • 13
    Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 144957.
  • 14
    Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004; 50: 134455.
  • 15
    Klatskin G, Conn HO. Histopathology of The Liver. New York: Oxford University Press, 1993.
  • 16
    DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 83745.
  • 17
    Zhou X, Obuchowski N, McClish D. : Statistical Methods in Diagnostic Medicine. New York: John Wiley & Sons, 2002.
  • 18
    Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39: 23944.